191934-25-5

Basic information

• Product Name: Benzoic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-, phenylmethyl ester
• CAS NO: 191934-25-5
• Molecular Formula: C19H21NO4
• Molecular Weight: 327.38
• Mol File: 191934-25-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-, phenylmethyl ester(191934-25-5)
• EPA Substance Registry System: Benzoic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-, phenylmethyl ester(191934-25-5)

Safety Data

• Hazardous Substances Data: 191934-25-5(Hazardous Substances Data)

Upstream product

• 66493-39-8 4-(N-tert-butoxycarbonyl)aminobenzoic acid 
• 100-39-0 benzyl bromide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 150-13-0 4-amino-benzoic acid 

Downstream Products

• 19008-43-6 benzyl 4-aminobenzoate 
• 325464-52-6 benzyl N-Boc-D,L-m-Tyr(O-Pyrim)-p-aminobenzoate 
• 325464-50-4 benzyl N-Boc-Tyr(O-2-Pyrim)-p-aminobenzoate 
• 1357619-92-1 benzyl 4-(2-bromoacetamido) benzoate 
• 1357619-94-3 benzyl 4-(2-(diethylamino)acetamido)benzoate 
• 1357619-95-4 benzyl 4-(2-(diisopropylamino)acetamido)benzoate 
• 1357619-96-5 benzyl 4-(2-(piperidin-1-yl)acetamido)benzoate 
• 1357619-97-6 benzyl 4-(2-morpholinoacetamido)benzoate 
• 302601-82-7 4-(2-(diethylamino)acetamido)benzoic acid 
• 1357620-02-0 4-(2-(diisopropylamino)acetamido)benzoic acid 
• 462067-20-5 4-(2-(piperidin-1-yl)acetamido)benzoic acid 
• 1357620-05-3 benzyl 4-(4-(dimethylamino)butanamido)benzoate 
• 1357620-06-4 benzyl 4-(4-morpholinobutanamido)benzoate 
• 751479-06-8 4-(4-(dimethylamino)butanamido)benzoic acid 

Relevant articles and documents

Design, synthesis and biological evaluation of 4′-demethyl-4-deoxypodophyllotoxin derivatives as novel tubulin and histone deacetylase dual inhibitors

A new class of 4′-demethyl-4-deoxypodophyllotoxin derivatives has been designed and synthesized as tubulin-HDAC dual inhibitors. Biological evaluation of these hybrids included the inhibitory activity of HDAC, in vitro cell cycle analysis in HCT-116 cells as well as cytotoxicity against two cancer cell lines (A549 and HCT116). The distance and angle between the HDAC capping group and the zinc binding group were systematically varied. Compounds 14a and 14c showed most potent dual inhibitory activity and powerful antiproliferative activity on HCT116 and A549 cell lines. This journal is

Development of potent and selective plasmin and plasma kallikrein inhibitors and studies on the structure-activity relationship

Based on structure-activity relationship studies, we designed and synthesized plasmin (PL) and plasma kallikrein (PK) inhibitors. Trans-(4-aminomethylcyclohexanecarbonyl)-Tyr(O-PIC)-octylamide inhibited PL, PK, urokinase (UK) and thrombin (TH) with IC50 values of 0.53, 30, 5.3 and >400 μM, respectively. Trans-(4-aminomethylcyclohexanecarbonyl)-Tyr(O-2-Pyrim)-4-carboxyanilide inhibited PL, PK, UK and TH with IC50 values of 36, 0.56, 440 and >1000 μM, respectively.